Celcuity Inc. Common Stock (CELC) Financials
Key financial figures for Celcuity Inc. Common Stock (Q2 2026).
Celcuity reported a Q2 2026 net loss of $78.9 million ($1.44/share) as SG&A climbed ahead of the REVTORPYK commercial launch, one week after the FDA approved the drug and the company raised $557.2 million in a June convertible note offering. Net loss was $78.9 million, or $1.44 per share, versus $45.3 million ($1.04/share) in Q2 2025; non-GAAP adjusted net loss was $58.7 million ($1.07/share) versus $40.5 million ($0.93/share) a year ago. R&D expense fell to $31.1 million from $36.4 million a year ago, driven by lower VIKTORIA-1 trial costs and lower license milestone costs, partially offset by higher headcount and manufacturing spend. On the outlook: Management expects current cash, cash equivalents and short-term investments to finance operations at least into 2029; REVTORPYK shipments are expected to begin late in the third quarter of 2026, and a supplemental NDA for the VIKTORIA-1 PIK3CA-mutant cohort is planned for submission in the third quarter of 2026. Figures are for Q2 2026, as Celcuity reported them.
- Revenue
- $0
- Net Income
- -$79M
- EPS
- $-1.44
- Total Assets
- $828M
- Operating Cash Flow
- -$55M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$79M | -$1.44 | -$55M | |
| Q1 FY2026 | $0 | -$53M | -$0.97 | -$55M | |
| Q4 FY2025 | $0 | -$51M | -$0.96 | -$36M | |
| Q3 FY2025 | $0 | -$44M | -$0.92 | -$45M | |
| Q2 FY2025 | $0 | -$45M | -$1.04 | -$36M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$177M | -$3.78 | -$154M | |
| FY2024 | $0 | -$112M | -$2.83 | -$84M | |
| FY2023 | $0 | -$64M | -$2.69 | -$54M |
Frequently asked questions
What was Celcuity's revenue last quarter?
Celcuity reported revenue of $0.00 for Q2 FY2026.
Is Celcuity profitable?
Not in its most recent reported period. Celcuity reported a net loss of $78.9 million for Q2 FY2026.
How much free cash flow did Celcuity generate?
Celcuity generated free cash flow of -$55.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Celcuity Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.